Radiation Oncology

Oncotype DX 21-gene recurrence scores may help select certain patients who are suitable to omit radiotherapy for early-stage breast cancer.

Grade 2 or higher genitourinary acute toxicity was observed in 27.3% of patients treated with 2 fractions of SBRT vs 29.2% of patients treated with 5 fractions.

Twice-daily radiotherapy prolongs survival vs once-daily radiation among those with LS-SCLC, even with the incorporation of immunotherapy.

The RadComp Consortium trial showed comparable HRQOL between proton and photon therapy for patients with non-metastatic breast cancer.

SBRT achieved a 5-year DFS rate of 89% vs 92% with moderately hypofractionated IMRT in patients with intermediate-risk prostate cancer.

Long-term data from the STARS trial affirm stereotactic radiation as a strong alternative to surgery for patients with operable stage I NSCLC.

The efficacy of TTFields was greater among patients who received immune checkpoint inhibition for the treatment of brain metastatic NSCLC.

The addition of 177Lu-PNT2002 did not significantly increase toxicity in patients with oligorecurrent prostate cancer who received SBRT.

No toxicity-related discontinuations were seen with adjuvant radiotherapy among patients with muscle-invasive bladder cancer.

Apalutamide plus stereotactic radiotherapy may be effective for certain patients with recurrent prostate cancer following radical prostatectomy.

In patients with rectal cancer, the median OS was 12 years in the chemotherapy and radiation therapy group vs 24 years in the chemotherapy alone group.

Results from a phase 2 trial showed a 1-year local control rate of 93.1% with SABR in patients with solid tumors who have uncomplicated bone metastases.

The cumulative chronic grade 3 or higher toxicity rate was 3% in patients treated with de-escalated adjuvant radiotherapy vs 11% with standard of care therapy.

Although radiotherapy was safe and well tolerated in patients with esophageal squamous cell carcinoma, more research is needed to confirm these results.

The retrospective study is the largest to evaluate the relationship between dose-averaged LET profiles and local control after CIRT for pancreatic cancer.

No treatment-related deaths were observed with radiotherapy for extensive-stage small cell lung cancer, and most adverse effects were grade 1 or 2.

The new formulation should increase the batch size by approximately 50% and will offer the potential to expand access to patients in new geographic locations.

Phase 3 data affirm the use of partial-breast intensity-modulated radiotherapy as a standard of care in patients with low-risk early-stage breast cancer.

Updated guidelines from ASTRO recommend various radiation therapy techniques for patients with WHO grade 4 adult-type diffuse glioma.

No tracer-related adverse effects were observed in the study, with [18F]AIF-NOTA-PCP2 showing acceptable dosimetry in patients with head and neck cancers.

Data support incorporating volumetric PET biomarkers into toxicity risk prediction for patients receiving CAR T-cell therapy for LBCL.

Compared with 18F-FDG, the use of 68Ga-NODAGA-LM3 appears to favor bone and brain lesion detection among patients with small cell lung cancer.

Stereotactic online adaptive magnetic resonance–guided radiation therapy was well tolerated and maintained stable QOL in patients with PDAC for up to 1 year.

Retrospective analysis at SNMMI 2025 revealed α-FRT with 225AC-3BP-3940 was well tolerated and elicited responses in pretreated metastatic breast cancer.

Use of PET-guided radiotherapy may enable the opportunity to incorporate biological information into the planning and delivery of radiation.